Integrated BioBank of Luxembourg publishes "2016 In Review"

NewsGuard 100/100 Score

IBBL (Integrated BioBank of Luxembourg) is pleased to publish  today  its  new  digital  annual report. “2016 In Review” looks back into the year 2016 in a refreshing way and highlights IBBL’s key achievements. Broadly speaking, it seems that IBBL has entered a transition phase in its history, having become a well established, valued and trusted partner in biomedical research.

Quality first

Quality has always been a key focus for IBBL, whose mission is to provide biospecimen-related services and a biobanking infrastructure for applied medical research. In 2016, IBBL successfully pursued this mission by passing follow-up audits for its ISO 9001 and NF S96-900 certifications, and extending the scope of its ISO 17025 accreditation* to 4 additional testing and characterisation methods. IBBL made history as it became the first biobank worldwide to be accredited for the next-generation 16S rRNA gene sequencing, a method that takes forward research into the microbial communities that inhabit the human body, known as the microbiome.

Together in Luxembourg

At national level, IBBL has continued advancing research in personalised medicine by working hand in hand with local hospitals and research institutes in areas such as cancer, diabetes, microbiome and Parkinson’s disease. The collected samples make a big difference for researchers, who discovered clear differences between people with and without diabetes in the way bacteria function, and identified a potential new tool to  test  cancer  patients  for  therapies  that  overcome  drug  resistance. Other  milestones  in  2016  were Luxembourg’s affiliation to EATRIS, the European infrastructure for translational medicine, and the launch of the Luxembourg Society for Microbiology.

Beyond borders

At the level of the Greater Region, IBBL teamed up with the Clinique Ambroise Paré and a private pathology laboratory from Thionville to establish the first France – Luxembourg cross-border collection of frozen tumour tissues, which can benefit both patients and cancer researchers. The project is a prime precedent for the tumourbank that IBBL is preparing together with all Luxembourgish hospitals and the Laboratoire National de Santé within the National Cancer Plan.

Another large-scale success is the selection of IBBL as the preferred biobank and scientific partner by EORTC (European Organisation for the Research and Treatment of Cancer). All in all, with 7 new contracts, 1 additional grant awarded by the European Commission and a high participation rate in its unique Biospecimen Proficiency Testing Programme, IBBL remained the central European biobanking infrastructure and bioservice provider for around 70 projects in 2016.

More than a traditional biobank

Besides the full range of bioservices that it provides, IBBL also carries out its own research focused on the quality of biospecimens. Led by Dr Betsou, the research department fulfills IBBL’s commitment to continuously improve the quality of its samples and services. In 2016, one of the projects explored the effect of 10 years of storage in -80°C freezers on thyroid cancer tissues.

Some others evaluated better ways to collect and handle biological samples, by comparing the impact of variations in temperature and delays during processing of blood samples on downstream metabolomics applications. IBBL also collaborates with industrial partners in the evaluation and validation of technologies, equipment and consumables. Its various research projects led to an outstanding number of 21 scientific articles published in peer-reviewed journals in 2016.

Towards new horizons

2017 is bringing about new challenges and opportunities. IBBL’s move to a permanent building in Dudelange will open a new chapter in its history and will allow the biobank to increase further the size and diversity of its services and sample collections. Among the handful of thrilling projects in the pipeline, some will reinforce national cooperation in developing better healthcare solutions, while others will enhance Luxembourg’s visibility in Europe and on the other side of the world.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tiny DNA circles are key drivers of cancer formation, study suggests